Tamoxifen for ER Positive Breast Cancer: 70 Real Stories

70 stories match breast cancer, ER positive and tamoxifen. 66 of them mention surgery.

Cancer Stories

Jenna, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40

Biomarkers: ER-positive

Jenna completed 10 rounds of chemotherapy and double mastectomy for ER-positive breast cancer with lymph-node involvement. She was recovering, planning reconstruction, and preparing for long-term tamoxifen.

breastcancer.org
OutcomeCare Ongoing
Tanya, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage II

Biomarkers: Genetic testing negative; Oncotype DX score 27; MammaPrint low risk; ER-positive

Tanya had Stage II ER-positive breast cancer with a large lobular tumor found on MRI, underwent bilateral mastectomy with immediate reconstruction, completed 4 rounds of chemotherapy, and started tamoxifen.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Nikoo, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Lobular Carcinoma: Nikoo's Patient Story

Patient Info: Nikoo, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: Peritoneum | Ascites | Possible bone

Nikoo’s early lobular breast cancer treated in 2003 with lumpectomy, radiation, and 5 years of tamoxifen recurred 19 years later as ER-positive, PR-positive, HER2-negative metastatic lobular breast cancer involving the peritoneum, ascites, and possible bone.

Lobular Breast Cancer Alliance
OutcomeSetback / Progression
Amelia, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient Story
OutcomeCare Ongoing
Cat, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient Story
OutcomeCancer-Free / NED
Natalie, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

Stage 0 HR-Positive Invasive Ductal Carcinoma: Natalie's Survivor Story

Patient Info: Natalie, Female | Stage 0

Biomarkers: ER-positive

As of June 2026, Natalie was living after Stage 0 DCIS, later nipple/Paget's disease recurrence, and 20 surgeries through May 2019, with a full life and ongoing attention to physical changes after reconstruction.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Tina, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV ER/PR-positive breast cancer with retinal vein and artery occlusion during endocrine-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 70%; PR 100%; HER2-negative; Ki-67 10%

Metastatic Site: bone (cranial vault, right first rib, sternum, D5, D6,…

As of November 2025, she continued care for Stage IV ER/PR-positive breast cancer with bone metastases while also managing severe left-eye retinal vascular occlusion and limited visual recovery.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage IIA ER/PR-positive mucinous breast cancer: tamoxifen plus cryoablation with no recurrence

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: ER/PR strongly positive, HER2 negative; CA15-3 and CEA remained normal during follow-up.

At approximately 32 months after cryoablation, the treated area had decreased to a less distinct 0.7 cm scar-like region, with no evidence of recurrence in either breast, axillae, or distant sites.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Breast CancerBreast Cancer

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

Stage 0 ER-positive DCIS: mastectomy without adjuvant therapy, followed by successful pregnancy

Patient Info: Anonymized, Female, 40s | Stage 0

Biomarkers: ER-positive; PgR-positive; HER2-negative; nuclear grade 2; comedo type; negative margins; no lymph node involvement

She completed surgical treatment for Stage 0 DCIS with negative margins and no lymph node involvement, avoided adjuvant therapy, resumed assisted reproductive treatment, and delivered a healthy male infant.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed Central
OutcomeCancer-Free / NED
Sara, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: Sara's Patient Story

Patient Info: Sara Glenn, Female, Under 40

Biomarkers: TP53 mutation / Li-Fraumeni syndrome; ER-positive; HER2-negative

As of June 2025, Sara had completed bilateral mastectomy and reconstruction for ER-positive, HER2-negative breast cancer and was on planned 10-year tamoxifen plus intensive Li-Fraumeni syndrome surveillance for herself and her daughters.

City of Hope
OutcomeCare Ongoing
Tanya, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer Alliance
OutcomeSetback / Progression
Kelsey, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient Story
OutcomeCare Ongoing